CN107667115B - 针对埃博拉病毒糖蛋白的人抗体 - Google Patents

针对埃博拉病毒糖蛋白的人抗体 Download PDF

Info

Publication number
CN107667115B
CN107667115B CN201680018389.XA CN201680018389A CN107667115B CN 107667115 B CN107667115 B CN 107667115B CN 201680018389 A CN201680018389 A CN 201680018389A CN 107667115 B CN107667115 B CN 107667115B
Authority
CN
China
Prior art keywords
antibody
ebov
antibodies
ebola virus
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680018389.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107667115A (zh
Inventor
C·基拉特索斯
W·奥尔森
P·梅森
N·斯塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55300806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107667115(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CN202110499070.6A priority Critical patent/CN113354732B/zh
Publication of CN107667115A publication Critical patent/CN107667115A/zh
Application granted granted Critical
Publication of CN107667115B publication Critical patent/CN107667115B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201680018389.XA 2015-01-26 2016-01-25 针对埃博拉病毒糖蛋白的人抗体 Active CN107667115B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110499070.6A CN113354732B (zh) 2015-01-26 2016-01-25 针对埃博拉病毒糖蛋白的人抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562107581P 2015-01-26 2015-01-26
US62/107,581 2015-01-26
US201562161356P 2015-05-14 2015-05-14
US62/161,356 2015-05-14
US201562245703P 2015-10-23 2015-10-23
US62/245,703 2015-10-23
PCT/US2016/014720 WO2016123019A1 (en) 2015-01-26 2016-01-25 Human antibodies to ebola virus glycoprotein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110499070.6A Division CN113354732B (zh) 2015-01-26 2016-01-25 针对埃博拉病毒糖蛋白的人抗体

Publications (2)

Publication Number Publication Date
CN107667115A CN107667115A (zh) 2018-02-06
CN107667115B true CN107667115B (zh) 2021-12-21

Family

ID=55300806

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680018389.XA Active CN107667115B (zh) 2015-01-26 2016-01-25 针对埃博拉病毒糖蛋白的人抗体
CN202110499070.6A Active CN113354732B (zh) 2015-01-26 2016-01-25 针对埃博拉病毒糖蛋白的人抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110499070.6A Active CN113354732B (zh) 2015-01-26 2016-01-25 针对埃博拉病毒糖蛋白的人抗体

Country Status (31)

Country Link
US (6) US9771414B2 (https=)
EP (2) EP3250591B1 (https=)
JP (4) JP6829199B2 (https=)
KR (1) KR102641731B1 (https=)
CN (2) CN107667115B (https=)
AU (2) AU2016211783B2 (https=)
BR (1) BR112017015845A2 (https=)
CA (1) CA2974899A1 (https=)
CL (3) CL2017001920A1 (https=)
CO (1) CO2017007619A2 (https=)
DK (1) DK3250591T3 (https=)
EA (1) EA038993B1 (https=)
ES (1) ES3054263T3 (https=)
FI (1) FI3250591T3 (https=)
HR (1) HRP20251642T1 (https=)
IL (1) IL253358B (https=)
LT (1) LT3250591T (https=)
MA (1) MA41421B1 (https=)
MD (1) MD3250591T2 (https=)
MX (2) MX392533B (https=)
MY (4) MY208081A (https=)
PH (1) PH12017501277B1 (https=)
PL (1) PL3250591T3 (https=)
PT (1) PT3250591T (https=)
RS (1) RS67563B1 (https=)
SG (2) SG11201705681YA (https=)
SI (1) SI3250591T1 (https=)
SM (1) SMT202500454T1 (https=)
TW (1) TWI710573B (https=)
UY (1) UY36538A (https=)
WO (1) WO2016123019A1 (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
CA3014435C (en) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Improved influenza b virus replication for vaccine development
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3487521A4 (en) 2016-07-21 2020-07-01 Emory University ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EA201990986A1 (ru) 2016-10-25 2019-09-30 Ридженерон Фармасьютикалз, Инк. Способы и системы анализа хроматографических данных
CN113512111B (zh) * 2017-03-10 2023-08-15 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
KR102659791B1 (ko) 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
US12162925B2 (en) * 2017-09-15 2024-12-10 The Wistar Institute Of Anatomy And Biology DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
BR112020010615A2 (pt) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
RU2686630C1 (ru) * 2017-12-22 2019-04-29 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire)
WO2019136029A1 (en) * 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
WO2019152607A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against ebola virus
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
CN108373500A (zh) * 2018-03-12 2018-08-07 中国科学院微生物研究所 一种热稳定性埃博拉治疗性抗体的制备及应用
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CA3089655C (en) 2018-03-19 2026-01-20 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
MX2020009851A (es) * 2018-03-26 2020-11-09 Regeneron Pharma Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos.
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020014443A1 (en) * 2018-07-12 2020-01-16 Vanderbilt University Pan-ebolavirus neutralizing human antibodies and methods of use therefor
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
AU2019333047A1 (en) 2018-08-30 2020-12-03 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN111138528B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8
CN111138531B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用
CN111138526B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用
CN111138527B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用
ES2942024T3 (es) 2019-01-16 2023-05-29 Regeneron Pharma Métodos para caracterizar enlaces disulfuro
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体
WO2021108548A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
GB201917480D0 (en) * 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
IL294375B1 (en) 2020-01-24 2026-02-01 Regeneron Pharma Stable antibody formulation
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
SG11202110145SA (en) 2020-02-26 2021-10-28 Vir Biotechnology Inc Antibodies against sars-cov-2 and methods of using the same
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
KR20240038138A (ko) * 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
AU2021332355A1 (en) 2020-08-31 2023-03-23 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
WO2022074630A1 (en) * 2020-10-09 2022-04-14 Auxilla Pharmaceuticals And Research Llp Liquid oral suspension of favipiravir
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
JP2024500409A (ja) 2020-12-17 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質封入マイクロゲルの作製
WO2022150809A1 (en) * 2021-01-05 2022-07-14 Immunome, Inc. Antibody cocktail against sars-cov-2 spike protein
KR20230134117A (ko) 2021-01-20 2023-09-20 리제너론 파마슈티칼스 인코포레이티드 세포 배양물에서 단백질 역가를 개선시키는 방법
IL305156A (en) 2021-03-03 2023-10-01 Regeneron Pharma Systems and methods for quantifying and modifying protein viscosity
EP4348234B1 (en) 2021-06-01 2026-04-08 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
JP2024531800A (ja) 2021-09-20 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体の不均一性を制御する方法
CA3230985A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Ph meter calibration and correction
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CA3236367A1 (en) 2021-10-26 2023-05-04 Michelle Lafond Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
JP2025503700A (ja) 2022-01-14 2025-02-04 レジェネロン ファーマシューティカルズ， インコーポレイテッド ベルカリンａ誘導体及びその抗体薬物複合体
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
US20240255519A1 (en) 2023-02-01 2024-08-01 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
EP4704808A1 (en) 2023-05-01 2026-03-11 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
CN121925272A (zh) 2023-09-29 2026-04-24 瑞泽恩制药公司 利用受控成核进行冻干
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
CN120943942A (zh) * 2024-09-12 2025-11-14 南京诺唯赞生物科技股份有限公司 特异性结合hpv的抗体
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same
CN120623329B (zh) * 2025-01-15 2026-04-10 中国人民解放军军事科学院军事医学研究院 抗埃博拉病毒vp40蛋白的纳米抗体3e07及在病毒检测中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094755A1 (en) * 2008-02-01 2009-08-06 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Monoclonal antibodies for ebola and marburg viruses
CN103864904A (zh) * 2014-03-04 2014-06-18 中国人民解放军军事医学科学院生物工程研究所 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630144B1 (en) 1999-08-30 2003-10-07 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies to Ebola glycoprotein
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US9097713B2 (en) 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
WO2016028503A1 (en) 2014-08-20 2016-02-25 Albert Einstein College Of Medicine, Inc. Therapy for filovirus infection
US9346875B2 (en) 2013-06-03 2016-05-24 Albert Einstein College Of Medicine, Inc. Therapy for filovirus infection
US20170183396A1 (en) 2014-02-19 2017-06-29 Jody Berry Ebola monoclonal antibodies
US20170158753A1 (en) 2014-06-25 2017-06-08 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
US10640549B2 (en) 2014-10-17 2020-05-05 University Of Virginia Patent Foundation Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094755A1 (en) * 2008-02-01 2009-08-06 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Monoclonal antibodies for ebola and marburg viruses
CN103864904A (zh) * 2014-03-04 2014-06-18 中国人民解放军军事医学科学院生物工程研究所 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection;Xiangguo Qiu;《PLoS Negl Trop Dis.》;20120320;第6卷(第3期);第2页右栏第1段，第2页左栏"Author Summary"部分 *
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice;Andrew J Murphy;《Proc Natl Acad Sci》;20140408;第111卷(第14期);第5153页摘要 *
Xiangguo Qiu.Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection.《PLoS Negl Trop Dis.》.2012,第6卷(第3期),第e1575页. *

Also Published As

Publication number Publication date
NZ733620A (en) 2024-09-27
MY189452A (en) 2022-02-14
MY196224A (en) 2023-03-23
US10081670B2 (en) 2018-09-25
WO2016123019A1 (en) 2016-08-04
SG11201705681YA (en) 2017-08-30
JP6829199B2 (ja) 2021-02-10
MY208081A (en) 2025-04-14
US11530255B2 (en) 2022-12-20
CL2017001920A1 (es) 2018-03-02
US20160215040A1 (en) 2016-07-28
MD3250591T2 (ro) 2026-02-28
AU2016211783A1 (en) 2017-07-27
MX2017009716A (es) 2018-04-24
EA038993B1 (ru) 2021-11-18
US12152067B2 (en) 2024-11-26
LT3250591T (lt) 2025-12-29
US10501526B2 (en) 2019-12-10
MX392533B (es) 2025-03-24
CN113354732A (zh) 2021-09-07
IL253358A0 (en) 2017-09-28
FI3250591T3 (fi) 2025-12-22
CL2020000498A1 (es) 2020-11-13
CA2974899A1 (en) 2016-08-04
JP2025065427A (ja) 2025-04-17
CO2017007619A2 (es) 2017-10-20
EA201791675A1 (ru) 2017-12-29
EP3250591A1 (en) 2017-12-06
US20210024617A1 (en) 2021-01-28
JP2023065648A (ja) 2023-05-12
CN107667115A (zh) 2018-02-06
US10829544B2 (en) 2020-11-10
RS67563B1 (sr) 2026-01-30
JP7796918B2 (ja) 2026-01-09
DK3250591T3 (da) 2025-12-22
US20240327501A1 (en) 2024-10-03
SG10202007835QA (en) 2020-09-29
MY180045A (en) 2020-11-20
PL3250591T3 (pl) 2026-01-26
US20200148751A1 (en) 2020-05-14
MA41421A (fr) 2017-12-05
EP4653051A2 (en) 2025-11-26
MA41421B1 (fr) 2026-02-27
IL253358B (en) 2021-07-29
AU2021202839A1 (en) 2021-06-03
JP2018506966A (ja) 2018-03-15
HRP20251642T1 (hr) 2026-02-13
EP4653051A3 (en) 2026-02-25
PH12017501277B1 (en) 2022-07-20
TW201639883A (zh) 2016-11-16
ES3054263T3 (en) 2026-02-02
UY36538A (es) 2016-08-31
US9771414B2 (en) 2017-09-26
EP3250591B1 (en) 2025-11-12
JP7672200B2 (ja) 2025-05-07
SI3250591T1 (sl) 2026-01-30
BR112017015845A2 (en) 2018-03-27
AU2016211783B2 (en) 2021-07-22
JP2020120683A (ja) 2020-08-13
TWI710573B (zh) 2020-11-21
PT3250591T (pt) 2025-11-19
CL2022003763A1 (es) 2023-06-30
US20190048066A1 (en) 2019-02-14
SMT202500454T1 (it) 2026-01-12
MX2021015687A (es) 2022-02-03
US20170355751A1 (en) 2017-12-14
KR102641731B1 (ko) 2024-02-29
PH12017501277A1 (en) 2018-01-29
CN113354732B (zh) 2024-07-09
KR20170102328A (ko) 2017-09-08

Similar Documents

Publication Publication Date Title
JP7796918B2 (ja) エボラウイルス糖タンパク質に対するヒト抗体
US11117955B2 (en) Anti-Zika virus antibodies and methods of use
CN108064240A (zh) 针对流感血凝素的人抗体
HK40127060A (en) Human antibodies to ebola virus glycoprotein
EA048493B1 (ru) Применение фармацевтических композиций человеческих антител к гликопротеину вируса эбола
OA18324A (en) Human antibodies to Ebola virus glycoprotein.
BR122025000707A2 (pt) Molécula polinucleotídica isolada, vetor, célula isolada, método de produção de um anticorpo ou fragmento de ligação ao antígeno do mesmo, e, conjunto de moléculas polinucleotídicas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant